Valuation : Beta Bionics, Inc.

Market Cap 874M 752M 707M 646M 1.21B 82.49B 1.21B 8.36B 3.24B 42.32B 3.28B 3.21B 136B P/E 2026 *
-9.1x
P/E 2027 * -9.03x
Enterprise Value 740M 637M 599M 547M 1.02B 69.87B 1.03B 7.08B 2.75B 35.85B 2.78B 2.72B 115B EV / Sales 2026 *
5.53x
EV / Sales 2027 * 4.46x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.51%
1 week-1.52%
Current month-2.66%
1 month+39.61%
3 months+39.81%
6 months+74.80%
Current year-36.27%
1 week 18.9
Extreme 18.905
20.23
1 month 14.07
Extreme 14.067
20.74
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-4,375 0.0097%
2/9/26 Sell

Executive/Senior Manager

-5,327 0.0118%
2/9/26 Sell

Chief Technology Officer

-4,221 0.0094%
Change 5-day change 1-year change 3-year change Capi.($)
-2.51%-1.52%-3.86% - 874M
-0.75%-1.35%+24.60%+13.24% 227B
-1.60%-3.89%+3.72%-20.39% 146B
-0.85%-1.58%-21.45%+19.18% 130B
+1.81%+2.05%-55.42%-10.32% 69.27B
+0.13%-0.34%+11.07%+18.34% 51.82B
+0.49%-1.32%-17.44%-13.87% 50.45B
+0.59%-1.94%+17.17%+27.06% 42.53B
-1.01%-1.28%+33.64%+48.14% 40.22B
-1.55%+1.22%+120.58%+36.88% 32.95B
Average -0.52%-1.56%+11.26%+13.14% 79.06B
Weighted average by Cap. -0.54%-1.55%+6.65%+8.04%

Financials

2026 *2027 *
Net sales 134M 115M 108M 99.02M 185M 12.64B 186M 1.28B 497M 6.49B 503M 492M 20.89B 180M 155M 145M 133M 249M 16.96B 249M 1.72B 667M 8.7B 675M 660M 28.04B
Net income -94.91M -81.67M -76.84M -70.19M -131M -8.96B -132M -908M -352M -4.6B -356M -349M -14.81B -96.44M -82.98M -78.08M -71.32M -133M -9.11B -134M -923M -358M -4.67B -362M -354M -15.05B
Net Debt -134M -115M -108M -98.89M -185M -12.62B -185M -1.28B -496M -6.48B -502M -491M -20.87B -73.32M -63.09M -59.36M -54.23M -101M -6.92B -102M -701M -272M -3.55B -275M -269M -11.44B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
04/09/26 USD 19.42 -2.51% 1,407,468
03/09/26 USD 19.92 +2.60% 1,403,535
02/09/26 USD 19.42 +1.81% 645,123
01/09/26 USD 19.07 -4.41% 564,366
31/08/26 USD 19.95 +1.17% 434,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.42USD
Average target price
20.31USD
Spread / Average Target
+4.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock